5-((2S)-4-(1-furano(4,5-c)pyridin-2-yl-isopropyl)-2-(N-(2,2,2-trifluoroethyl)carbamoyl)piperazinyl)(4S,2R)-N-((3S,4S)-3-hydroxychroman-4-yl)-4-hydroxy-2-benzylpentanamide

InChIKey	`WMTSGCIMPPZQLI-LZVMDTAVSA-N`
Compound Name	5-((2S)-4-(1-furano(4,5-c)pyridin-2-yl-isopropyl)-2-(N-(2,2,2-trifluoroethyl)carbamoyl)piperazinyl)(4S,2R)-N-((3S,4S)-3-hydroxychroman-4-yl)-4-hydroxy-2-benzylpentanamide
Canonical SMILES	`CC(C)(c1cc2cnccc2o1)N1CCN(C[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3OC[C@H]2O)[C@H](C(=O)NCC(F)(F)F)C1`
Clinical Status	Data-mined Candidate
Targets (Human+Pathogen)	2
Pfam Stratification	Homologous
Avg pChEMBL	9.48
Source	BindingDB;ChEMBL

2D Structure

Activity Profile

Target	Gene	Organism	Category	Pfam	pChEMBL	Type	Source
P04585	gag-pol	Human immunodeficiency virus type 1 group M subtype B (isolate HXB2)	Pathogen	PF00540 PF19317 PF00552 PF02022 PF00075 PF00665 PF00077 PF00078 PF06815 PF06817 PF00098	10.2	IC50	BindingDB
Q72874	pol	Human immunodeficiency virus type 1	Pathogen	PF00077	8.8	IC50	ChEMBL